Annexon, Inc. (ANNX)
| Market Cap | 444.77M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -134.24M |
| Shares Out | 91.14M |
| EPS (ttm) | -1.77 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,455,599 |
| Open | 4.750 |
| Previous Close | 4.660 |
| Day's Range | 4.690 - 5.060 |
| 52-Week Range | 1.570 - 8.400 |
| Beta | 1.15 |
| Analysts | Strong Buy |
| Price Target | 14.67 (+200.62%) |
| Earnings Date | May 14, 2024 |
About ANNX
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in P... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for ANNX stock is "Strong Buy." The 12-month stock price forecast is $14.67, which is an increase of 200.62% from the latest price.
News
Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting
Additional data from the Phase 2 ARCHER trial demonstrating protection of visual acuity and anatomical structure following ANX007 treatment will be featured as an oral presentation
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living wit...
Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
BRISBANE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devast...
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy (GA) Expected in mid-2024, a...
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living wit...
Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference
BRISBANE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with ...
Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon's Novel Therapeutic Approach
Virtual event on Friday, March 1, 2024 at 10:00 AM ET Event will feature GBS experts Lisa Butler of the GBS|CIDP Foundation International, Hugh Willison, MBBS, PhD, Professor Emeritus of Neurology of ...
Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases
ANX005 Phase 3 Pivotal Data in Guillain-Barré Syndrome (GBS) On Track for First Half of 2024;Potential to be First Approved Treatment for GBS Patients in the U.S.
Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with ...
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
BRISBANE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical ...
Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint
Alignment with FDA on Best Corrected Visual Acuity ≥ 15-Letter Loss as Primary Outcome Measure - Representing the Highest Value Outcome to Patients and Physicians
Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway
Target Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity
Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference
BRISBANE, Calif., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with...
Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results
Company Prioritizes Greatest Near-term Value-Driving Programs: ANX005 for Guillain-Barré Syndrome (GBS), ANX007 for Geographic Atrophy (GA) and First-in-Kind Complement Small Molecule, ANX1502
Annexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference
BRISBANE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with ...
Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy
PRIME Designation Granted Based on Phase 2 ARCHER Trial Results, which Showed Meaningful Preservation of Visual Function in Patients with Geographic Atrophy
Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS)
ANX005 Granted Orphan Drug Designation by the European Medicines Agency for the Treatment of GBS Target Enrollment Achieved in Phase 3 Pivotal Study of ANX005 in GBS Representing the Company's Third S...
Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference
BRISBANE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with cla...
Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results
ARCHER Trial Results Presented at ASRS Further Demonstrate Preservation of Visual Function in Patients with Geographic Atrophy; Company to Engage Regulatory Agencies to Determine Optimal Path Forward
Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy
Additional analyses support consistent protection from vision loss Annexon to engage with regulatory agencies to determine optimal path forward for ANX007 Company to hold investor conference call on M...
Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer
BRISBANE, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patien...
Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023
Company to hold investor conference call on Monday, July 31, 2023 at 1:30 p.m. PT / 4:30 p.m. ET Company to hold investor conference call on Monday, July 31, 2023 at 1:30 p.m. PT / 4:30 p.m. ET
Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function
ARCHER data support ANX007 as the first complement therapy to preserve visual acuity, achieving statistically significant protection against vision loss in both foveal and non-foveal patients through ...
Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress
Initial Clinical Data Expected from the Phase 2 ARCHER Trial of ANX007 in Geographic Atrophy in Mid-2023 Initial Clinical Data Anticipated from the Phase 1b Trial of ANX009 in Lupus Nephritis in 1H'23...
Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference
BRISBANE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical ...